Jul 29, 2020| JD Health

Traditional Chinese Medicine Master Diangui Li Joins JD Health

Rachel Liu

by Rachel Liu

Dr. Diangui Li, Traditional Chinese Medicine Master officially joins JD Health today. JD Health also signed an agreement with China Research Association of Chinese Medicine (CRACM) to jointly promote innovation in the area of traditional Chinese medicine and the development of “internet + Chinese medicine”.

Dr. Li and Lijun Xin, CEO of JD Health, attended today’s signing ceremony.

Dr. Li and Lijun Xin, CEO of JD Health, attended today’s signing ceremony

Dr. Li, who will turn 70 next month, is a professor at the Traditional Chinese Medicine College of Hebei Province. He was granted the title of “National Master of TCM” by the central government of China. He enjoys great fame in the treatment of precancerous lesions of stomach and gastritis.

Dr. Li is the honorary director of Hebei Province Hospital of Traditional Chinese Medicine. He has laid the foundation of “Zhuo-Du Theory”, which is a theory for treating stomach diseases. After joining JD, Dr. Li will also take the leadership of the Zhuo-Du Theory Studies Center at JD Health’s Traditional Chinese Medicine (TCM) Consultation Center. He plans to utilize his studies on the theory to help more JD customers with their ailments and provide professional online traditional Chinese medicine consultations on the JD Health platform.

This June, JD Health launched its TCM Consultation Center, which brings together experts from various TCM hospitals. This center can not only provide patients with online and group consultations, but also tailored services. For example, with the online prescription function, doctors can give patients TCM prescriptions for a variety of forms of Chinese medicine.

Lijun Xin said, “Moving forward, JD Health will continue to promote the culture of traditional Chinese medicine, drive its development through technology, and build a brand-new ecosystem where the internet and traditional Chinese medicine come together.”

(liuchang61@jd.com)

Dec 25, 2024| JD Health, JD Retail

JD Report: Five Health Consumption Trends for 2024

Vivian Yang

On December 24th, JD.com’s Consumption and Industry Development Research Institute, in collaboration with HealthInsight, a media think tank specializing in the health sector, released an insightful analysis of China’s 2024 health consumption landscape. The report outlines five key trends in the health industry, highlighting the increasing consumer demand for proactive health management and the industry’s evolving dynamics.

The Rise of Weight Management Solutions

Modern lifestyles have contributed to rising obesity rates with 34.3% of Chinese adults classified as overweight and 16.4% as obese. Obesity is associated with over 200 diseases, posing significant health risks. The introduction of semaglutide, a GLP-1 receptor agonist for long-term weight management, in China marks a promising development. The market for GLP-1 weight loss drugs in China is projected to exceed 37.852 billion RMB by 2030. On JD.com, searches related to “weight management” have increased more than 3.8 times year-on-year, with growing demand for diet products and home fitness equipment such as kettlebells and leg trainers.

Addressing the Growing Mental Health Concerns
With 95 million people in China affected by depression, mental health is an increasing concern. Consumers are turning to books, stress-relief toys, online consultations, and meditation to manage stress. On JD.com, searches for “mental health” have doubled, with significant interest in emotional release tools and psychological books. JD Health’s Internet Hospital now offers specialized clinics with over 2,300 counselors addressing issues like anxiety, depression, and sleep disorders.

The Booming Sleep Economy
Over 300 million Chinese experience sleep disorders, often due to irregular schedules. The sleep economy is booming with the market size reaching 495.58 billion RMB in 2023 and expected to surpass 600 billion RMB by 2027. JD.com has seen a 210% increase in searches for sleep aids, with high demand for sleep headphones, eye masks, and nutritional supplements. Sales of sleep-enhancing pillows and mattresses have also grown significantly.

Everyday Integration of Medical Devices

The home medical device market is expanding as consumers increasingly monitor their health independently. Products like heart rate-monitoring smartwatches and glucose meters are becoming household staples. This year, JD.com data shows that purchases of vision care devices and smart health monitoring equipment have tripled. The market for home medical devices is expected to reach 380 billion RMB by 2025.

Shifting Focus to Preventive Health Management

Emphasizing early screening and intervention, JD.com has seen a significant rise in orders for health services such as genetic testing and early cancer screening. These trends highlight a shift from treatment to prevention, driven by technological advancements and policy support. As consumer awareness grows, health consumption is becoming a major force in economic development, presenting opportunities for rapid growth in the health industry.

In conclusion, the 2024 health consumption landscape is characterized by a strong shift towards proactive health management and the integration of technology into everyday health practices. These trends not only reflect changing consumer priorities but also indicate significant growth opportunities for businesses in the health sector. JD.com remains committed to supporting these developments by providing innovative products and services tailored to the evolving needs of consumers across the dynamic health sector.

(vivian.yang@jd.com)

Dec 12, 2024| Global Partners/ Brands, JD Health

JD Health Debuts Merck’s New Diabetes Medication GLUCOPHAGE® XR (Reduce Mass) Online in China

Vivian Yang

On December 10, JD Health, in collaboration with Merck, a globally renowned biopharmaceutical leader, began offering GLUCOPHAGE® XR (Reduce Mass), the metformin hydrochloride extended-release tablets, and became the first online pharmacy in China to provide the new antidiabetic medication developed by Merck. This launch signifies a major milestone in the partnership between JD Health and Merck, which is dedicated to enhancing the online availability and accessibility of innovative treatments for type 2 diabetes patients in China, thereby offering them a more convenient and effective medication experience.

GLUCOPHAGE® has been a cornerstone in the treatment of type 2 diabetes for over 60 years worldwide. The latest version of this medication is designed to enhance patient adherence by reducing the long-term burden of medication administration while maintaining its therapeutic benefits. The use of GSD sustained-release technology extends the time the medication remains in the stomach, reduces gastrointestinal irritation, and improves drug absorption. Additionally, the tablet is now smaller, has reduced volume by 30%, and has been transitioned from a capsule to a round shape, making it easier to swallow. It requires only once-daily administration, significantly enhancing patient convenience and safety.

To celebrate the online launch collaboration, JD Health and Merck hosted a special release event for the new medication at the 7th China International Import Expo in November. This event followed their partnership agreement in September, which also marked the opening of Merck China’s self-operated flagship store on JD.com.

With a large user base, robust supply chain, and rich medical service resources, JD Health has become a preferred partner to launch many chronic disease medications online. By seamlessly integrating online and offline resources, JD Health ensures that new drug information reaches the right users swiftly, offering convenient purchasing options and improving drug accessibility and usage efficiency. Additionally, JD Health’s extensive logistics network ensures timely and secure delivery of medications, enhancing user experience and building trust.

(vivian.yang@jd.com)

Report: JD Comprises 28.86% of China’s Home Appliance Sales Share